论文部分内容阅读
目的评价抗帕金森病(Parkinson’s disease,PD)新药沙芬酰胺的作用机制、药动学行为、临床试验及安全性等,为临床用药提供参考。方法查阅相关文献30篇。结果与结论沙芬酰胺是一种α-氨基酰胺衍生物,既可抑制多巴胺的再摄取,又可高效、选择性和可逆性地抑制单胺氧化酶-B的活性。此外,沙芬酰胺还是谷氨酸释放抑制剂,具有钠离子通道阻滞作用和钙离子通道调节作用。临床用于突发性帕金森成年患者的辅助治疗,在中期至晚期波动患者中,单独或与其他帕金森药物联合使用可以稳定左旋多巴的剂量。其应用前景良好。
Objective To evaluate the mechanism, pharmacokinetic behavior, clinical trials and safety of safenamide, a new drug against Parkinson’s disease (PD), and provide a reference for clinical use. Methods access to relevant literature 30. RESULTS AND CONCLUSIONS Safranamide is an α-aminoamide derivative that inhibits the reuptake of dopamine and inhibits monoamine oxidase-B activity with high efficiency, selectivity, and reversibility. In addition, safenamide is also a glutamate release inhibitor, with sodium ion channel block and calcium channel regulation. Clinically for the adjuvant treatment of patients with sudden Parkinson’s disease in adult patients with mid to late fluctuations alone or in combination with other Parkinson drugs can stabilize the dose of levodopa. Its application prospects are good.